U.S. FDA says Empowered Diagnostics recalling COVID-19 tests

Reuters
Updated ·1 min read
FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland

(Reuters) - Empowered Diagnostics LLC is recalling its COVID-19 tests as they have not been cleared for use in the United States and could potentially lead to false results, the U.S. Food and Drug Administration (FDA) said on Friday.

The regulator has labeled the recall of the CovClear COVID-19 rapid antigen test and the ImmunoPass COVID-19 neutralizing antibody rapid test as Class 1, or the most serious type of recall.

It cautioned people to stop using the two tests, which have been distributed with labeling that incorrectly indicates that they are authorized by the FDA.

The company could not be immediately reached for comment.

Empowered Diagnostics initiated the recall in December and has pulled back at least 284,575 antigen tests and 2,100 antibody tests in the United States, according to the regulator.

The CovClear test is currently authorized in Canada and the European Union, according to the company's website.

(Reporting by Amruta Khandekar; Editing by Devika Syamnath)